Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INND-301
- Development stage
- Preclinical
- Lead developer
- InnDura Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
INND-301 is a preclinical-stage immunotherapy being developed by InnDura Therapeutics for the treatment of EGFR-expressing solid tumors. The therapeutic utilizes a CD7-targeted lipid nanoparticle (LNP) delivery system to transport mRNA encoding the EVE16 immune receptor directly to immune effector cells. The EVE16 receptor is engineered based on the CD16A (FcγRIIIA) framework and is designed to redirect these immune cells to recognize and eliminate tumor cells expressing the Epidermal Growth Factor Receptor (EGFR). This approach aims to provide a targeted, off-the-shelf mRNA-based solution for solid malignancies by harnessing the body's own immune effector cells.
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD7 (CD7 antigen)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on INND-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INND-301.